Every material Form 8-K Mobia Medical, Inc. has filed with the SEC since August 03, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Mobia Medical reported third quarter 2026 revenue of $15.6 million, up 73% from $9.0 million a year earlier, and raised its full year 2026 revenue guidance to $57.0 million to $57.5 million. The net loss widened to $17.3 million from $11.4 million, although the per-share loss narrowed to $0.52 from $13.31 after the company's IPO increased its share count.
Q3 2026 revenue was $15.6 million, up from $9.0 million in Q3 2025; gross margin was 83.2% versus 79.6%.
Net loss was $17.3 million in Q3 2026, compared with $11.4 million in Q3 2025; operating expenses rose 71% to $31.5 million.
Full year 2026 revenue guidance was raised to $57.0 million to $57.5 million, from $54.0 million to $56.0 million previously.
Cash and cash equivalents totaled $160.7 million as of September 30, 2026.
Mobia Medical reported second-quarter 2026 revenue of $13.5 million, up 102% from a year earlier, and gave full-year 2026 revenue guidance of $54.0 million to $56.0 million. Operating expenses rose 83% to $29.2 million, and the net loss widened to $21.0 million from $10.5 million, so revenue growth came with a larger loss for shareholders.
Q2 2026 revenue $13.5 million vs. $6.7 million in Q2 2025; gross margin 83.2% vs. 82.3%
Net loss $21.0 million vs. $10.5 million a year earlier; loss per share $1.10 vs. $12.44, reflecting more weighted-average shares after the IPO
Full-year 2026 revenue outlook $54.0 million to $56.0 million, growth of 69% to 75%
Cash and cash equivalents $177.1 million at June 30, 2026, including about $134.0 million net IPO proceeds
Effective July 30, 2026, Mobia Medical expanded its board from seven to eight members and appointed Myriam J. Curet, M.D. as a Class II director. The board determined she is independent, and she has not yet been named to any board committee.
Dr. Curet's term expires at the 2028 annual meeting of stockholders.
She retired in March 2026 as Executive Vice President and Chief Medical Officer of Intuitive Surgical, a role she held from November 2017.
She also sits on the boards of Inspire Medical Systems (since December 2023) and Stereotaxis (since July 2021).
She will receive compensation under Mobia's non-employee director program and is expected to sign the company's standard indemnification agreement.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Mobia Medical, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →